New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
14:32 EDTAZN, PFEAstraZeneca may sell rights to some future income to boost defenses, FT says
AstraZeneca (AZN) is working with bankers to explore the sale of future income streams from some of its existing drugs as a way to raise "billions of dollars in cash" and boost its defenses against any renewed takeover bid from Pfizer (PFE), said Financial Times, citing people familiar with the matter. Reference Link
News For AZN;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 28, 2015
07:12 EDTPFEPfizer lowers FY15 adjusted EPS view to $1.95-$2.05 from $2.00-$2.10
Consensus $2.07. Lowers FY15 revenue guidance to $44B-$46B from $44.5B-$46.5B, consensus $45.94B.
07:09 EDTPFEPfizer reports Q1 adjusted EPS 51c, consensus 49c
Subscribe for More Information
April 27, 2015
15:04 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
14:41 EDTPFEEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:41 EDTPFE, AZNTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTPFE, AZNPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
06:19 EDTAZNAstraZeneca says smaller M&A deals more realistic, Reuters reports
Subscribe for More Information
06:07 EDTAZNAstraZeneca reiterates outlook for FY15
Subscribe for More Information
06:06 EDTAZNAstraZeneca reports Q1 core EPS $1.08, consensus $1.05
Reports Q1 revenue $6.06B, consensus $5.95B. Reports Q1 Symbicort revenue $845M vs. $928M last year, Pulmicort revenue $286M vs. $263M last year, Crestor revenue $1.17B vs. $1.33B last year, Nexium revenue $644M vs. $930M last year.
05:39 EDTAZNCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
05:37 EDTAZNAstraZeneca signs co-development agreement with Innate Pharma
Subscribe for More Information
April 23, 2015
15:01 EDTAZNNotable companies reporting before tomorrow's open
Subscribe for More Information
08:25 EDTAZNJuno Therapeutics, MedImmune announce immuno-oncology trial collaboration
Subscribe for More Information
April 22, 2015
08:04 EDTAZNBIND Therapeutics presents data on BIND-014, AZD2811 at AACR
Subscribe for More Information
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
07:06 EDTAZNBina Tech, AstraZeneca announce collaborative agreement for GMS
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use